
|Articles|February 5, 2004
Group establishes guidelines for drug studies of relapsed prostate Ca patients
A group of three leading cancer centers has developed guidelines to determine which prostate cancer patients at risk for relapse should participate in a clinical trial and which compounds are appropriate in these studies.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











